Previous Article | Next Article ![]()
Infection and Immunity, October 2003, p. 5700-5713, Vol. 71, No. 10
0019-9567/03/$08.00+0 DOI: 10.1128/IAI.71.10.5700-5713.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.
Xue Q. Liu,1 David Jackson,2,3 Juan Cooper,1 and Michael F. Good1,2*
The Queensland Institute of Medical Research,1 The CRC for Vaccine Technology, Brisbane 4029 ,2 Department of Microbiology, The University of Melbourne, Parkville 3052, Australia3
Received 17 March 2003/ Returned for modification 26 May 2003/ Accepted 18 July 2003
The Plasmodium merozoite surface protein 1 (MSP1) is a leading vaccine candidate for protecting against the blood stage of malaria. Previous studies have shown that the 19-kDa carboxyl terminus of this protein is able to induce protective immunity in some monkey and mouse strains. We show that immunization with the recombinant Plasmodium yoelii 19-kDa fragment of MSP1 (MSP119) expressed in Saccharomyces cerevisiae (yMSP119) can induce protective antibodies in several inbred mouse strains and one outbred mouse strain. However, mice expressing the H-2s major histocompatibility complex haplotype are unable to generate yMSP119-specific antibodies. While synthetic peptides derived from MSP119 are immunogenic in B10.S mice, they cannot function as helper epitopes, and immunization with yMSP119 does not induce T cells that recognize the recombinant protein or synthetic peptides corresponding to its sequence. Nonresponsiveness could be overcome by using chemical linkers to conjugate yMSP119 to diphtheria toxoid (DT), resulting in immunogens capable of inducing protective yMSP119-specific antibodies in both MSP119-responsive and otherwise nonresponsive mouse strains. The ability of sera from mice immunized with the conjugate to inhibit binding of a protective monoclonal antibody (MAb 302) to yMSP119 correlated strongly with a delay in the prepatent period. Chemical conjugation of yMSP119 to DT may be a preferred method to enhance immunogenicity, as carrier priming experiments demonstrated that an existing immune response to DT enhanced a subsequent antibody response to yMSP119 after vaccination with yMSP119-DT. These results have important implications for the development of a malaria vaccine to protect a population with diverse HLAs.
Present address: Malaria Vaccine Development Unit, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»